Abstracts Archive - Page 2050 of 2425 - ACR Meeting Abstracts

Abstract Number: 30 • 2014 ACR/ARHP Annual Meeting
Inhibiting Autocrine Interleukin-6 (IL-6) Trans-Signalling in Human CD14^+VE Monocultures Reduces Osteoclast Differentiation
Lauren A. Jordan¹, Fraser L. Collins², Simon A. Jones¹, Ernest H. Choy³, Ann K. Harvey¹ and Anwen S. Williams¹, ¹Cardiff University, Institute of Infection and Immunity, School of Medicine, Cardiff, United Kingdom, ²Michigan State University, Department of Physiology, East Lansing, MI, ³Section of Rheumatology, Cardiff University, Institute of Infection and Immunity, School of Medicine, Cardiff, United Kingdom
Background/Purpose: Interleukin-6 (IL-6) and the inflammatory CC-chemokine CCL3 are highly expressed in rheumatoid arthritis, juvenile idiopathic arthritis and multiple myeloma. While these mediators contribute to…
Abstract Number: 29 • 2014 ACR/ARHP Annual Meeting
Impaired Bone Healing in Patients Suffering from Rheumatoid Arthritis – Anti-Inflammatory Therapy As Confounder
Annemarie Lang¹, Sarah Fuegener², Paula Hoff², Anastasia Rakow³, Manuela Jakstadt⁴, Timo Gaber⁴, Gerd Burmester², Carsten Perka³ and Frank Buttgereit⁵, ¹Berlin-Brandenburg School of Regenerative Therapies (BSRT), Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ³Center for Musculoskeletal Surgery, Orthopedic Department, Charité University Medicine, Berlin, Germany, ⁴Berlin-Brandenburg Center of Regenerative Therapies (BCRT), Berlin, Germany, ⁵Charité University Hospital, Berlin, Germany
Background/Purpose Anti-inflammatory treatment of rheumatoid arthritis (RA) with glucocorticoids (GC) and/or non-steroidal anti-inflammatory drugs (NSAIDs) is supposed to negatively influence bone metabolism and healing. It…
Abstract Number: 28 • 2014 ACR/ARHP Annual Meeting
Evidence for Receptor Activator of NF-Kb (RANK)-Independent Bone Erosion in the Cherubism Mouse Model of Inflammatory Arthritis
William R. O'Brien¹, Julia F. Charles², Kelly Tsang¹ and Antonios O. Aliprantis¹, ¹Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Rheumatology, Allergy and Immunology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: A gain-of-function mutation in the adaptor Src Homology 3 Binding Protein 2 (SH3BP2) causes Cherubism, a rare pediatric disease marked by aggressive bone remodeling…
Abstract Number: 27 • 2014 ACR/ARHP Annual Meeting
CD115⁺ Osteoclast Precursors Arise before Clinical Onset of Arthritis and Are Regulated By Proinflammatory Cytokines
Antonia Puchner¹, Victoria Saferding², Eliana Goncalves-Alves³, Silvia Hayer⁴, Harald Leiss¹, Josef Smolen⁵, Kurt Redlich⁶ and Stephan Blüml¹, ¹Department of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Rheumatology, Medical University of Vienna, Vienna, Austria, ³rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁵Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁶Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose Bone erosions and systemic bone loss in rheumatoid arthritis patients results from an increased activity of osteoclasts, which are derived from precursor cells of…
Abstract Number: 26 • 2014 ACR/ARHP Annual Meeting
Functional Osteoclasts Differentiate Spontaneously from the Rheumatoid Joint
Stinne Greisen¹, Halldór Bjarki Einarsson², Malene Hvid³, Ellen Margrethe Hauge^4,5, Bent Deleuran^3,6 and Tue Kragstrup⁷, ¹Dept of Biomedicine, Aarhus University, Aarhus, Denmark, ²Dept. of Biomedicine, Aarhus University, Aarhus, Denmark, ³Department of Biomedicine, Aarhus University, Aarhus, Denmark, ⁴Dept. of Anatomi, Aarhus University, Aarhus, Denmark, ⁵Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁶Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁷Aarhus University, Aarhus, Denmark
Functional osteoclasts differentiate spontaneously from the rheumatoid joint Background/Purpose Osteoimmunology is a field of emerging interest in which bone formation and resorption are understood in…
Abstract Number: 25 • 2014 ACR/ARHP Annual Meeting
DC-STAMP Modulates Osteoblast Differentiation and Regulates Bone Repair
Yahui Grace Chiu¹, Tzong-Ren Sheu², Jinbo Li³, Dongge Li¹, Michael Thullen², Brendan Boyce⁴, Edward Puzas² and Christopher T. Ritchlin⁵, ¹Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ²Center for Musculoskeletal Research, University of Rochester, Rochester, NY, ³Pathology, University of Rochester, Rochester, NY, ⁴Pathology, University of Rochester, Rocehster, NY, ⁵Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose Patients with osteoporosis and the elderly have an increased risk of bone fracture. Currently, no biomarker is available to assess bone healing status in…
Abstract Number: 24 • 2014 ACR/ARHP Annual Meeting
Netrin1 Is Highly Expressed and Required in Inflammatory Infiltrates in Wear Particle-Induced Osteolysis
Aranzazu Mediero¹, Bhama Ramkhelawon², Ed Purdue³, Steven R. Goldring⁴, Kathryn Moore² and Bruce N. Cronstein⁵, ¹Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, ²Leon H. Charney Division of Cardiology, Department of Medicine,, NYU School of Medicine, New York, NY, ³535 East 70th Street, Hospital for Special Surgery, New York, NY, ⁴Hospital for Special Surgery, New York, NY, ⁵NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose Osteoclasts play a critical role in homeostatic bone turnover and pathologic bone destruction. Netrin-1, expressed in the marrow only by osteoclast precursors, acts in…
Abstract Number: 23 • 2014 ACR/ARHP Annual Meeting
Activation of EPAC1/2 Is Essential for Osteoclast Formation By Modulating NFkB Nuclear Translocation and Actin Cytoskeleton Rearrangements
Aranzazu Mediero¹, Miguel Perez-Aso² and Bruce N. Cronstein³, ¹Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, ²545 1st Ave., New York University, New York City, NY, ³NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose Bisphosphonates inhibit osteoclast differentiation/function via inhibition of Rap1A isoprenylation and cytoskeletal assembly. As Rap1 is the effector of EPAC proteins (exchange protein directly activated…
Abstract Number: 1 • 2014 ACR/ARHP Annual Meeting
Lymphocyte Proliferation to a Cross-Reactive Gut Commensal Candidate in Antiphospholipid Syndrome
William Ruff¹, Silvio M. Vieira², Cassyanne Aguiar^3,4, John Sterpka², Andrew Goodman⁵, Doruk Erkan^3,6 and Martin Kriegel^1,7, ¹Immunobiology, Yale School of Medicine, New Haven, CT, ²Yale School of Medicine, New Haven, CT, ³New York Presbyterian/Weill Cornell Medical Center, New York, NY, ⁴Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Microbial Pathogenesis, Yale School of Medicine, Microbial Diversity Institute, New Haven, CT, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Medicine, Section of Rheumatology, Yale School of Medicine, New Haven, CT
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune clotting disorder of unknown etiology targeting a major autoantigen, β2-glycoprotein I (β2GPI). Infectious triggers have been implicated in…
Abstract Number: L12 • 2014 ACR/ARHP Annual Meeting
Immunological Phenotyping of a Cohort of American Travelers with Chikungunya Viral Arthritis
Jonathan Miner¹, Han Xian Aw yeang¹, Julie Fox¹, Samantha Taffner¹, Alfred Kim², Michael Diamond¹, Deborah Lenschow³ and Wayne Yokoyama^1,4, ¹Department of Medicine, Washington University in Saint Louis School of Medicine, Saint Louis, MO, ²Medicine, Washington University in Saint Louis School of Medicine, Saint Louis, MO, ³Washington University in Saint Louis School of Medicine, Saint Louis, MO, ⁴Howard Hughes Medical Institute, Saint Louis, MO
Background/Purpose: Chikungunya virus (CHIKV) is a rapidly emerging arthritogenic mosquito-borne alphavirus that spread to the United States in 2014. After an initial period of acute…
Abstract Number: L8 • 2014 ACR/ARHP Annual Meeting
Differential DNA Methylation Associated with Lupus Nephritis
Renuka Nayak¹, Sharon A. Chung², Joanne Nitiham³ and Lindsey A. Criswell³, ¹Rheumatology, University of California - San Francisco, San Francisco, CA, ²School of Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ³Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA
Background/Purpose: Genetic and epigenetic factors contribute to the progression of systemic lupus erythematosus (SLE). We now have technologies that allow us to identify these factors…
Abstract Number: L14 • 2014 ACR/ARHP Annual Meeting
Determination of Efficacy of Intra-Articular Infliximab Therapy in JIA Patients By 3D/4D Musculo-Skeletal Ultrasound
Miroslav Harjacek¹, Mandica Vidovic², Lovro Lamot^2,3, Marija Perica² and Lana Tambic Bukovac², ¹Rheumatology, Children's Hospital Srebrnjak, Zagreb, Croatia, ²Children's Hospital Srebrnjak, Zagreb, Croatia, ³University of Zagreb School of Medicine, Zagreb, Croatia
Background/Purpose: Intra-articular (IA) infliximab (IFX) is an attractive treatment option of chronic arthritis, but based on few heterogenic studies, outcome is still controversial. To investigate…
Abstract Number: L20 • 2014 ACR/ARHP Annual Meeting
BOW015, a Biosimilar Infliximab, in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Doses: 54-Week Results of a Randomized, Double-Blind, Active Comparator Study
Jonathan Kay¹, Michael Wyand², Srikantiah Chandrashekara³, Davy Jacob Olakkengil⁴, Kaushik Bhojani⁵, Girish Bhatia⁶, Gaurav Rathi⁷, Suresh Maroli⁸, Elizabeth Thomson⁹, Cheryl Lassen¹⁰, Lucy Shneyer¹¹ and Arvind Chopra¹², ¹UMass Memorial Medical Center, Worcester, MA, ²Epirus Biopharmaceuticals, Boston, MA, ³Chanre Rheumatology and Immunology Centre and Research, Bangalore, India, ⁴St. John’s Medical College Hospital, Bengaluru, India, ⁵Department of Rheumatology, Fortis Hospital, Mumbai, India, ⁶Pentagon Multispeciality Clinic and Research Centre, Pune, India, ⁷Rathi Hospital, Ahmedabad, India, ⁸Reliance Life Sciences, Mumbai, India, ⁹Elizabeth Thomson LTD, London, MA, United Kingdom, ¹⁰Epirus Biopharmaceuticals, Zug, Switzerland, ¹¹Shneyer Statistics LLC, Denville, NJ, ¹²Rheumatology, Center for Rheumatic Diseases, Pune, India
Background/Purpose: Over the first 16 wks of this phase 3 double-blind (DB) comparative effectiveness clinical trial, the comparable proportion of ACR20 responders for BOW015 (a…
Abstract Number: 15 • 2014 ACR/ARHP Annual Meeting
Performance of an Automated Chemiluminescence Assay for Anti-Cardiolipin and Anti-Beta2glycoprotein I Antibodies Detection in a Cohort of 400 Clinically Characterized Consecutive Routine Samples
Alessandra Zanola¹, Laura Andreoli¹, Cecilia Nalli¹, Flavio Allegri¹, Michael Mahler², Gary Norman³ and Angela Tincani¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Research, INOVA Diagnostics, San Diego, CA, ³INOVA Diagnostics, San Diego, CA
Background/Purpose: Several immunoassays are available for the detection of anti-cardiolipin (aCL) and anti-beta2glycoprotein I antibodies (anti-B2GPI), but standardization and harmonization of these tests is an…
Abstract Number: 14 • 2014 ACR/ARHP Annual Meeting
Rivaroxaban Use in Patients with Antiphospholipid Syndrome Patients and Previous Poor Anticoagulation Control with Vitamin K Antagonists
Savino Sciascia¹ and Beverley Hunt², ¹Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, ²St Thomas Hospital, London, UK, Thrombosis and Thrombophilia Center (St Thomas Hospital, London, UK), London, United Kingdom
Background/Purpose: Management of antiphospholipid syndrome (APS) centres on attenuating the procoagulant state whilst balancing the bleeding risks of anticoagulant therapy. In a minority of APS…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].